Coherus BioSciences announced recognition and support for Rare Cancer Day to raise awareness for rare cancers such as nasopharyngeal carcinoma. “Rare cancers, such as NPC, affect under-served populations, and raising awareness among patients and the medical community is critical for early detection and treatment leading to improved survival rates,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. “Patient advocacy groups, such as TargetCancer Foundation and NORD Rare Cancer Coalition, play an important role in raising awareness for rare cancers through their partnerships with the government and companies developing treatments to improve outcomes for patients.” Additionally, Coherus recognizes the importance of and applauds the bipartisan Congressional resolution introduced in the U.S. House of Representatives on September 26, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Coherus Biosciences receives FDA CRL for UDENYCA ONBODY BLA
- FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
- Coherus BioSciences Announces New Employment Inducement Grants
- Coherus Completes Surface Oncology Acquisition
